« Back
Home /
Tigecycline (hydrochloride)

Tigecycline (hydrochloride)

Item no.	HY-B0117A-5mg
Manufacturer	MedChem Express
CASRN	197654-04-9
Amount	5 mg
Category	Oncology Neuroscience Neural Lineage Markers By Cell Type Blastoma Carcinoma Cell Biology Cell Status Proliferation Inhibitors & Compound Libraries Small Molecules By Organ Bladder Cancer
Type	Inhibitors
Specific against	other
Purity	99.56
Citations	[1]Jitkova Y, et al. A novel formulation of tigecycline has enhanced stability and sustained antibacterial and antileukemic activity. PLoS One. 2014 May 28;9(5):e95281.\|[2]Falagas ME, et al. Activity of TP-6076 against carbapenem-resistant Acinetobacter baumannii isolates collected from inpatients in Greek hospitals. Int J Antimicrob Agents. 2018 Aug;52(2):269-271. Ann Lab Med. 2021 May 1;41(3):293-301. Emerg Microbes Infect. 2024 Dec;13(1):2321981. Adv Ther (Weinh). 2024 Jan 12. Anim Dis. 2021;1(1):26. Ann Clin Microbiol Antimicrob. 2024 Aug 20;23(1):73. Antimicrob Agents Chemother. 2019 May 24;63(6). pii: e00470-19. Antimicrob Agents Chemother. 2023 Feb 16;67(2):e0145922. Antimicrob Agents Chemother. 2024 Mar 6;68(3):e0112023. Antimicrob Agents Chemother. 2024 Oct 29:e0094524. Antimicrob Agents Chemother. 2025 May 23:e0024925. Authorea. 2025 Sep 17. Biomed Pharmacother. 2023 Dec 31:169:115856. Cell Rep. 2025 Nov 25;44(11):116496. Cell. 2025 May 15;188(10):2757-2777.e22. Clin Exp Pharmacol Physiol. 2023 Jul;50(7):604-609. Cureus. 2024 Dec 1;16(12):e74917. EBioMedicine. 2022 Apr;78:103943. Infect Drug Resist. 2020 Jul 28;13:2617-2629. Infect Drug Resist. 2021 Jun 30;14:2499-2507. Infect Drug Resist. 2023 Apr 17:16:2271-2279. Infect Drug Resist. 2025 Oct 4:18:5239-5247. Infect Genet Evol. 2025 Sep:133:105780. Int J Antimicrob Agents. 2018 Aug;52(2):269-271. Int J Antimicrob Agents. 2025 Jun 9:107551. J Antibiot (Tokyo). 2022 Aug;75(8):463-471. J Antimicrob Chemother. 2025 Apr 10:dkaf105. J Appl Microbiol. 2025 Apr 17:lxaf093. Microb Pathog. 2020 Dec;149:104502. Microbiol Spectr. 2023 Feb 14;11(1):e0323822. Microbiol Spectr. 2023 Jun 15;11(3):e0071823. Microbiol Spectr. 2025 Mar 19:e0134424. Microorganisms. 2024 Mar 13;12(3):575. Nat Commun. 2022 Mar 2;13(1):1116. Nat Commun. 2024 Jun 28;15(1):5481. Naunyn Schmiedebergs Arch Pharmacol. 2025 Oct 29. SLAS Discov. 2020 Sep;25(8):895-905. Vet Microbiol. 2024 May:292:110046. World J Microbiol Biotechnol. 2024 Jun 6;40(8):233.
Smiles	O=C(C(C1=O)=C(O)[C@@H](N(C)C)[C@]2([H])C[C@]3([H])CC4=C(C(C3=C(O)[C@@]21O)=O)C(O)=C(NC(CNC(C)(C)C)=O)C=C4N(C)C)N.Cl
ECLASS 10.1	32160490
ECLASS 11.0	32160490
UNSPSC	12000000
Alias	GAR-936 hydrochloride
Shipping Condition	Room temperature
Available
Manufacturer - Type	Reference compound1
Manufacturer - Applications	Cancer-programmed cell death
Manufacturer - Category	Reference compound / Active compounds; API
Shipping Temperature	Room Temperature
Storage Conditions	4°C (Powder, sealed storage, away from moisture)
Product Description	Tigecycline hydrochloride (GAR-936 hydrochloride) is a broad-spectrum glycylcycline antibiotic. The mean inhibitory concentration (MIC) of Tigecycline for E. coli (MG1655 strain) is approximately 125 ng/mL[1]. MIC50 and MIC90 are 1 and 2 mg/L for Acinetobacter baumannii (A. baumannii), respectively[2].
Manufacturer - Research Area	Cancer; Infection
Solubility	10 mM in DMSO
Manufacturer - Pathway	Anti-infection; Autophagy
Clinical information	Launched
UNSPSC Code	12352005

Note: The presented information and documents (Manual, Product Datasheet, Safety Datasheet and Certificate of Analysis) correspond to our latest update and should serve for orientational purpose only. We do not guarantee the topicality. We would kindly ask you to make a request for specific requirements, if necessary.

All products are intended for research use only (RUO). Not for human, veterinary or therapeutic use.